Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Heron Therapeutics Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.76 (market cap $3.06B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is far larger — about 41.3× Heron Therapeutics Inc's market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 15 Days and Heron Therapeutics Inc for 35 Days on average.
| FLRN | HRTX | |
|---|---|---|
Market Cap | $3.06B | $74.04M |
Volume | 465,116 | 3,668,095 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $1.49 |
52-Week Low | $30.65 | $0.27 |
Typical Hold Time | 15 Days | 35 Days |
Enterprise Value | — | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.75 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF maintains consistent $0.11 quarterly dividend payments through 2026, providing income stability amid current market volatility.
FLRN offers protection against rising interest rates with near-zero duration exposure, though significant financial sector concentration presents risk. Current market sentiment reflects cautious optimism as institutional investors add positions while technical indicators suggest near-term pressure. The floating rate structure positions FLRN favorably in inflationary environments.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
